Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Regeneron Pharmaceuticals Inc.
Headquarters: Tarrytown, NY, United States of America
Website: https://www.regeneron.com/
Year Founded: 1988
Status: Public
Industry Sector: HealthTechnology
CEO: Leonard S. Schleifer, MD, PhD
Number Of Employees: 15,106
Enterprise Value: $75,915,485,302
PE Ratio: 14.27
Exchange/Ticker 1: NASDAQ:REGN
Exchange/Ticker 2: N/A
Latest Market Cap: $59,734,085,632
BioCentury | Apr 9, 2025
Data Byte
Early pains, late gains for biopharmas on Wall Street
Biotech and pharma indexes reacted to a pair of signals from the White House on tariffs, resulting in a drastic turnaround
BioCentury | Apr 4, 2025
Data Byte
First PDUFA date missed on RFK Jr.’s watch
FDA has at least seven more target action dates coming up in April
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 27, 2025
Product Development
Pancreatic cancer therapies progress despite mixed investor response
BioCentury’s latest clinical report highlights therapies that extended pancreatic cancer survival
BioCentury | Feb 27, 2025
Product Development
Crispr Therapeutics: Controlled risk for accelerated development
An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy
BioCentury | Jan 22, 2025
Management Tracks
Fabrice Chouraqui to become CEO of Pharming
Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 10, 2025
Management Tracks
Odyssey hires Jason Haas as CFO
Plus: CMO changes at Centessa, Lifordi, Rapport and Gemma, and updates from Peptone, Labgenius, Mitorx and more
Items per page:
1 - 10 of 1756